HIV and Peripheral Artery Disease: Acknowledging the Association

The role of human immunodeficiency virus (HIV) in the development of vascular disease (specifically peripheral artery disease) remains unclear. Is the virus per se the direct cause of this disease or is it a consequence of dyslipidemia, one of the adverse effects of antiretrovirals?

This study looked into the effect of HIV infection on peripheral artery disease after adjusting for all traditional risk factors in a large cohort of HIV+ patients and compared them with an uninfected population of similar baseline characteristics.

 

Of 91953 participant patients with a mean follow up of 9 years, researchers observed 7708 peripheral vascular events. Events rate per 1000 patient/year was higher among HIV+ patients (11.9% vs 9.9%).


Read also: MITRA-FR: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.


After adjusting for multiple demographic factors, traditional cardiovascular risk factors and other covariates, it was observed that HIV+ patients have higher incidence of peripheral vascular events, and the difference turned out to be significant (HR 1.19, CI 95%, 1.13 to 1.25).

 

Events risk was 1.5 fold higher in patients with viral load >500 copies/ml and nearly 2 fold higher in those with CD4 cell counts <200 cells/mm3, even though this had no effect in amputations rate. On the contrary, HIV+ patients with undetectable viral load and with CD4 cell counts ≥500/mm³ had identical events rate as uninfected patients.


Read also: OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis.


Mortality after vascular event was higher regardless HIV infection.

 

Conclusion

HIV infection was associated with a 19% increased risk of peripheral artery disease, beyond that explained by traditional risk factors. For patients with CD4 cell counts <200/mm³, risk resulted nearly 2-fold higher, whilst patients under control had similar risk as HIV negatives.

 

Original title: Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease.

Reference: Joshua A. Beckman et al. Circulation. 2018;138:255–265.

 

2018-09-10 HIV-y-vascular-periferica.full


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...